D1 Capital Partners L.P. - 31 Mar 2025 SCHEDULE 13G/A Report for Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value (LXEO)

Filing Manager
D1 Capital Partners L.P.
Reporting Manager
D1 Capital Partners L.P.
Security
Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value
Symbol
LXEO
Shares outstanding
33,746,621 shares
Disclosed Ownership
978,652 shares
Ownership
2.9%
Form type
SCHEDULE 13G/A
Filing time
15 May 2025, 09:58:26 UTC
Date of event
31 Mar 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"D1 Capital Partners L.P. disclosed 2.9% ownership in Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value (LXEO) on 31 Mar 2025."

Quick Takeaways

  • D1 Capital Partners L.P. filed SCHEDULE 13G/A for Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value (LXEO).
  • Disclosed ownership: 2.9%.
  • Date of event: 31 Mar 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 15 May 2025, 09:58.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (2)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
D1 Capital Partners L.P. 2.9% 978,652 0 978,652 /s/ Amanda Hector Amanda Hector, General Counsel and Chief Compliance Officer
Daniel Sundheim 2.9% 978,652 0 978,652 /s/ Daniel Sundheim Daniel Sundheim, Individually

Sponsored